Kou Mengying, Deng Ying
Department of Oncology, Maoming People's Hospital, Maoming City, Guangdong Province, China.
Department of Gastroenterology, Maoming People's Hospital, No.101 Weimin Road, Maonan District, Maoming City, Guangdong Province, 525000, China.
Int J Colorectal Dis. 2024 Dec 17;39(1):203. doi: 10.1007/s00384-024-04785-7.
To explore the potential of circulating tumor DNA (ctDNA) as a prognostic biomarker to predict treatment response and survival outcomes in patients with metastatic colorectal cancer (mCRC).
A retrospective analysis was conducted on 134 patients with mCRC who were treated between January 2020 and December 2021. The patients were classified into ctDNA-negative and ctDNA-positive groups based on plasma ctDNA detection. Demographic, clinical, and laboratory parameters, treatment response, survival outcomes, and adverse events were recorded and analyzed.
No significant differences were observed in baseline characteristics between the two groups. Compared to the ctDNA-positive patients, ctDNA-negative patients exhibited superior outcomes, including a higher objective response rate (65.22% vs. 46.15%), disease control rate (81.16% vs. 63.08%), progression-free survival (8.24 ± 1.02 vs. 7.86 ± 0.91 months), overall survival (24.58 ± 3.58 vs. 23.27 ± 3.46 months), and 1-year survival rate (73.91% vs. 55.38%). The ctDNA-positive group had a significantly higher incidence of adverse events. Correlation analyses revealed significant associations between ctDNA status, tumor markers, treatment response, and survival outcomes.
ctDNA is a promising noninvasive biomarker for predicting treatment response, survival, and adverse events in mCRC, potentially guiding personalized therapeutic strategies.
探讨循环肿瘤DNA（ctDNA）作为预后生物标志物预测转移性结直肠癌（mCRC）患者治疗反应和生存结局的潜力。
对2020年1月至2021年12月期间接受治疗的134例mCRC患者进行回顾性分析。根据血浆ctDNA检测结果将患者分为ctDNA阴性组和ctDNA阳性组。记录并分析人口统计学、临床和实验室参数、治疗反应、生存结局及不良事件。
两组患者的基线特征无显著差异。与ctDNA阳性患者相比，ctDNA阴性患者的结局更佳，包括更高的客观缓解率（65.22%对46.15%）、疾病控制率（81.16%对63.08%）、无进展生存期（8.24±1.02对7.86±0.91个月）、总生存期（24.58±3.58对23.27±3.46个月）和1年生存率（73.91%对55.38%）。ctDNA阳性组不良事件发生率显著更高。相关性分析显示ctDNA状态、肿瘤标志物、治疗反应和生存结局之间存在显著关联。
ctDNA是一种有前景的非侵入性生物标志物，可用于预测mCRC患者的治疗反应、生存情况和不良事件，有可能指导个性化治疗策略。
